Josh Richardson
Private Equity Investor at THE GOLDMAN SACHS GROUP, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Solomon | M | 62 | 25 years | |
| John Rogers | M | 68 | 30 years | |
| Michael Heffernan | M | 59 |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 5 years |
| David Viniar | M | 68 | 25 years | |
| Georgia Erbez | F | 57 |
Neurana Pharmaceuticals, Inc.
 Neurana Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA. | 3 years |
| John Waldron | M | 55 | 24 years | |
| Brian Lee | M | 57 | 30 years | |
| Darrin Miles | M | - |
Nested Therapeutics, Inc.
 Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | - |
| Jan Tighe | M | 61 | 6 years | |
| George Lee | M | - | 30 years | |
| Kevin Johnson | M | 63 | 2 years | |
| Kimberley Harris | F | 53 | 3 years | |
| Marc Nachmann | M | - | 30 years | |
| Denis Coleman | M | 51 | 28 years | |
| Ashok Varadhan | M | - | 26 years | |
| Peter Oppenheimer | M | 61 | 10 years | |
| Carey Halio | F | - | 25 years | |
| Klaus Hoeflich | M | - |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | - |
| Sheara Fredman | F | 49 | 22 years | |
| Arvin Dar | M | - |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | - |
| Lakshmi Niwas Mittal | M | 73 | 16 years | |
| Paul Wotton | M | 63 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
| Thomas Montag | M | 67 | 1 years | |
| Ellen Kullman | F | 68 | 8 years | |
| M. Burns | F | 66 | 13 years | |
| Kathryn Ruemmler | F | 53 | 4 years | |
| Mark Flaherty | M | 64 | 10 years | |
| Douglas R. Carlson | M | 45 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 2 years |
| Bill Chu | M | - | - | |
| Max Ritter | M | - | - | |
| Tom Malafronte | M | - | - | |
| Michael Broadbery | M | - | - | |
| Manuel Camacho | M | - | - | |
| Rodolfo Pérez | M | - | - | |
| Brian Pasquinelli | M | - | - | |
| James Ellery | M | - | - | |
| Matt Kilsby | M | - | - | |
| Jared Cohen | M | 42 | 2 years | |
| Darius Naraghi | M | - | - | |
| Steven Budig | M | - | - | |
| Nicole Weeldreyer | F | - | - | |
| Yuriy Podoshev | M | - | - | |
| Elaine Rene | F | - | - | |
| Chris Semones | M | - | - | |
| Mark Maislish | M | - | - | |
| Diego Fortunati | M | - | - | |
| Megan Hogan | F | - | - | |
| Marguerite Bion | F | - | - | |
| Chris Buddin | M | - | - | |
| Yasmine Bassili | F | - | - | |
| Rajesh Venkataramani | M | - | - | |
| Janki Gandhi | F | - | - | |
| Carlo Rizzuto | M | 53 |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | - |
| Fran Bermanzohn | F | 65 | - | |
| Adriana Tajonar | M | - |
Nested Therapeutics, Inc.
Nested Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nested Therapeutics, Inc. is a biotechnology company based in Cambridge, MA. The company focuses on discovering and developing novel, targeted, small molecule precision medicine therapies for cancer patients. The company uses mutation clusters to identify druggable pockets and have a platform that utilizes insights from genomics, computational chemistry, proteomics, and AI. Nested Therapeutics aims to advance precision oncology medicine by finding new driver mutations to reach a broader group of patients. The company was founded by Arvin Dar and Klaus Hoeflich. The CEO is Darrin Miles. | - |
| Jan Hatzius | M | - | 4 years | |
| Jyothsna Natauri | F | 46 | - | |
| Marco Argenti | M | - | 5 years | |
| Richard J. Gnodde | M | - | 37 years | |
| Russell W. Horwitz | M | - | 1 years | |
| Omid Veiseh | M | - |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
| Hidehiro Imatsu | M | - | - | |
| Cyril Goddeeris | M | - | - | |
| David Binnion | M | - | - | |
| Tanya Baker | F | - | 16 years | |
| Clifton Marriott | M | - | - | |
| Robert Drake-Brockman | M | - | - | |
| Marie Kirk | F | - | 2 years | |
| Francesco Pascuzzi | M | - | - | |
| Jeroen Rombouts | M | - | - | |
| Zaid Khaldi | M | - | - | |
| Scott Morenstein | M | 48 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
| Raghav Maliah | M | - | - | |
| Douglas De Filippi | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mary Christina Thomson | F | 53 | 2 years | |
| Ivan S. Coulter | M | - |
Sublimity Therapeutics Ltd.
 Sublimity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland. | 15 years |
| Stephen Dilly | M | 64 | 2 years | |
| Nick Glover | M | 55 | 6 years | |
| Albert Agro | M | 59 |
Sublimity Therapeutics Ltd.
Sublimity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland. | - |
| Mary Kerr | M | 63 |
KaNDy Therapeutics Ltd.
 KaNDy Therapeutics Ltd. BiotechnologyHealth Technology KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom. | 3 years |
| Neil Carter | M | - |
University of Virginia
| 11 years |
| John Smalley | M | - |
University of Virginia
| 12 years |
| Zachary Bratun Glennon | M | - |
University of Virginia
| 4 years |
| Howard Hechler | M | - |
University of Virginia
| 4 years |
| Thomas Decarlo | M | - |
University of Virginia
| - |
| Rachel C Cantor | F | - |
University of Virginia
| 4 years |
| JJ Kasper | M | - |
University of Virginia
| 8 years |
| Rahul Gorawara | M | - |
University of Virginia
| 5 years |
| Christy Oliger | F | 54 | 1 years | |
| Daniel J. Estes | M | 43 | 2 years | |
| Craig Collard | M | 58 | 2 years | |
| Andrew Sinclair | M | 52 | 3 years | |
| Chris Carroll | M | - |
University of Virginia
| 4 years |
| Tran Nguyen | M | 50 | 3 years | |
| Mona Ashiya | M | 55 | 3 years | |
| Gaurav Aggarwal | M | 51 | 3 years | |
| Donald Parfet | M | 71 | 4 years | |
| Nicole Onetto | M | 71 | 4 years | |
| Max Leykin | M | - |
University of Virginia
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 96.97% |
| Ireland | 2 | 2.02% |
| United Kingdom | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Josh Richardson
- Personal Network
